Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients

Shi Zhou,* Samrat Khanal,* Haijun Zhang Department of Oncology, Zhongda Hospital, Medical School of Southeast University, Nanjing, Jiangsu, People’s Republic of China *These authors contributed equally to this work Purpose: The aim of this study was to evaluate the risk of immune-related ad...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Zhou S, Khanal S, Zhang H
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Dove Medical Press 2019-01-01
Σειρά:	Therapeutics and Clinical Risk Management
Θέματα:	immune-related adverse events immune checkpoint inhibitors nivolumab ipilimumab lung cancer melanoma
Διαθέσιμο Online:	https://www.dovepress.com/risk-of-immune-related-adverse-events-associated-with-ipilimumab-plus--peer-reviewed-article-TCRM
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!